ACTUATE THERAPEUTICS, INC. — Investor Relations & Filings
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies for cancers with high unmet medical needs. The company's lead drug candidate is elraglusib, a novel, first-in-class small molecule inhibitor of glycogen synthase kinase-3 (GSK-3). Elraglusib is being developed for difficult-to-treat cancers, including metastatic pancreatic cancer. Its mechanism of action targets multiple molecular pathways involved in promoting tumor growth and resistance to conventional drugs. Additionally, it functions as a mediator of anti-tumor immunity by inhibiting immune checkpoints and regulating immune cell function. The company's goal is to develop therapies that can slow, stop, or shrink tumors with minimal adverse effects, thereby improving patient outcomes.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| CURRENT REPORT | 2026-05-22 | English | |
| INITIAL REGISTRATION STATEMENT | 2026-05-14 | English | |
| FORM 10-Q FOR MAR 2026 | 2026-05-14 | English | |
| 8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer) | 2026-05-11 | English | |
| 8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer) | 2026-05-06 | English | |
| ARS - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer) | 2026-04-09 | English |
Browse filings by year
9 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
11 filings
| |||||
| 46860567 | CURRENT REPORT | 2026-05-22 | English | ||
| 46258235 | INITIAL REGISTRATION STATEMENT | 2026-05-14 | English | ||
| 46272889 | FORM 10-Q FOR MAR 2026 | 2026-05-14 | English | ||
| 45003345 | 8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer) | 2026-05-11 | English | ||
| 41855421 | 8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer) | 2026-05-06 | English | ||
| 33934987 | ARS - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer) | 2026-04-09 | English | ||
| 33640232 | DEF 14A - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer) | 2026-04-06 | English | ||
| 33052004 | 10-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer) | 2026-03-26 | English | ||
| 31149129 | 4 Filing | 2026-02-13 | English | ||
| 12907859 | FORM 8-K | 2026-01-12 | English | ||
| 12907857 | Director's Dealing 2026 | 2026-01-07 | English | ||
|
2025
4 filings
| |||||
| 12907861 | Major Shareholding Notification 2025 | 2025-12-17 | English | ||
| 12907858 | Regulatory Filings 2025 | 2025-12-11 | English | ||
| 12907865 | CURRENT REPORT | 2025-11-28 | English | ||
| 12907864 | SUPPLEMENT TO PROSPECTUS DATED 9-8-25 | 2025-11-28 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
|
Adaptimmune Therapeutics PLC
Commercial-stage biopharma developing TCR T-cell therapies …
|
ADAP | GB | Manufacturing |
ACTUATE THERAPEUTICS, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33867/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33867 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33867 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33867 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33867}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ACTUATE THERAPEUTICS, INC. (id: 33867)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.